-
Morning Market Movers (NSM, NVGN, QCOR, CBST)
Tuesday, April 5, 2011 - 9:46am | 157National Semiconductor Corp (NYSE: NSM) climbed 71.07% to $24.07 at 9:45 am. Texas Instruments Inc (NYSE: TXN) announced its plans to acquire NSM for $6.5 billion or $25 per share, representing a 78% premium to NSM's closing price on Monday. Novogen Limited (NASDAQ: NVGN) surged 52.67% to $2.00....
-
Preview: Ispire Pharma To Resume Trading At 10am (ISPH)
Tuesday, April 5, 2011 - 9:33am | 18Preview: Ispire Pharma To Resume Trading At 10am (NASDAQ: ISPH)
-
Inspire Pharma Halted, News Pending (ISPH)
Tuesday, April 5, 2011 - 9:31am | 15Inspire Pharma Halted, News Pending (NASDAQ: ISPH)
-
Gabelli Downgrades CEPH Rating To Hold
Tuesday, April 5, 2011 - 9:30am | 151Gabelli & Company, based upon the details surrounding the possible acquisition of Cephalon (NASDAQ: CEPH) by Valeant Pharmaceuticals (NYSE: VRX), is advising investors and shareholders to Hold CEPH. Claiming that the bid could go higher than initially proposed at $73 per share, Gabelli writes...
-
Trading Halted: Inspire Pharmaceuticals, News Pending (ISPH)
Tuesday, April 5, 2011 - 9:17am | 16Trading Halted: Inspire Pharmaceuticals (NASDAQ: ISPH), News Pending
-
Biotech/Pharma Stocks; Merck (NYSE:MRK) to Acquire Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH)
Tuesday, April 5, 2011 - 9:00am | 58WHITEHOUSE STATION, N.J. & RALEIGH, N.C. - April 5, 2011 (Investorideas.com Newswire) - Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) today announced that they have entered into a definitive agreement under which Merck will...
-
Biotech/Pharma Stocks; Merck (NYSE:MRK) to Acquire Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH)
Tuesday, April 5, 2011 - 9:00am | 58WHITEHOUSE STATION, N.J. & RALEIGH, N.C. - April 5, 2011 (Investorideas.com Newswire) - Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) today announced that they have entered into a definitive agreement under which Merck will...
-
Lazard Upgrades Cubist Pharmaceuticals To Buy, $33 PT
Tuesday, April 5, 2011 - 8:42am | 46Lazard Capital Markets has upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Hold to Buy and has established a $33 price target following the settlement of patent litigation with Teva Pharmaceuticals (NASDAQ: TEVA).
-
Needham Raises PT On Cubist Pharmaceuticals To $33
Tuesday, April 5, 2011 - 8:17am | 41Needham has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $27 to $33 and following the company's settlement with Teva (NASDAQ: TEVA). Buy rating maintained.
-
Benzinga's Top Pre-Market NASDAQ Gainers (CBST, QCOR, EXPE, ONNN)
Tuesday, April 5, 2011 - 8:10am | 166Cubist Pharmaceuticals Inc (NASDAQ: CBST) rose 15.84% to $29.25 in the pre-market session. CBST settled a patent lawsuit with Teva Pharmaceuticals (NASDAQ: TEVA) associated to its Cubicin drug. Questcor Pharmaceuticals Inc (NASDAQ: QCOR) added 15.01% to $17.16 in the pre-market session. QCOR...
-
Amin Announces Phase 3 MARINE Trial Data to be Presented in May at the National Lipid Association 2011 Annual Scientific Sessions
Tuesday, April 5, 2011 - 8:05am | 168Amarin Corporation plc (Nasdaq: AMRN) today announced that data from the MARINE trial, a pivotal Phase 3 study investigating AMR101 as a treatment for very high triglycerides, will be presented at the National Lipid Association 2011 Annual Scientific Sessions at the Sheraton New York Hotel and...
-
Trading Halted Optimer Pharmaceuticals Stock Due to FDA Advisory Committee Reviewing Fidaxomicin Data in Clostridium difficile Infection
Tuesday, April 5, 2011 - 8:01am | 65Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that NASDAQ has halted trading of the Company's common stock this morning. The Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) is scheduled to meet today to review and discuss Optimer's New...
-
Oppenheimer Reports On QCOR 1Q11 Estimates
Tuesday, April 5, 2011 - 7:48am | 123Oppenheimer has issued a report regarding the first quarter estimates for Questcor Pharmaceuticals (NASDAQ: QCOR). According to the report, "Importantly, 1Q11 Acthar scripts demonstrated strong growth, with total vials shipped up 20% sequentially from 1,680 in 4Q10. In our view, the consistent...
-
Trading Halted: Optimer Pharmaceuticals, News pending (OPTR)
Tuesday, April 5, 2011 - 7:24am | 16Trading Halted: Optimer Pharmaceuticals (NASDAQ: OPTR), news pending
-
Mylan Launches Generic Version of Sandostatin
Tuesday, April 5, 2011 - 7:15am | 131Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma has launched Octreotide Acetate Injection USP, pre-filled syringes, the generic version of Novartis' Sandostatin®, a treatment for a rare hormonal disorder called acromegaly. Octreotide Acetate Injection is also used to...